Sigumir Peptide: How To Read The Khavinson A-Number System

Most people searching for the Sigumir peptide arrive confused, and it is not their fault. The same dietary supplement is sold as Sigumir, as Sigumir A-4, and under three or four house brand names. Some sellers call it natural. Others sell something called Cartalax and say it does the same job.

I have supplied this group of peptide bioregulators since 2015 and I still get the same email every week. Which one is the real one.

The naming is not random. There is a system underneath it. Once you can read the system, every product in the catalog becomes obvious, including the ones we do not sell. This page teaches you to read it, using the Sigumir peptide as the worked example.

Part one of twoWhat the A number tells you

The A number is a tissue code. It is not a dose, not a strength, and not a version. Every natural peptide bioregulator in this line carries one.

Each natural complex was made by taking tissue from young animals, then separating out the short peptide chains inside it. The A number records which tissue that was.

So the number is not telling you A-20 outranks A-4. It is telling you one came from bone marrow and the other came from cartilage and bone tissues. They are addresses, not rankings.

That is a sample, not the full catalog. We are building the complete code map as its own reference page. If you want to see how the same logic plays out in another tissue group, our guides to the kidney peptides and the heart peptide use the identical structure.

Two practical consequences fall out of this.

Sigumir and Sigumir A-4 are the same thing. One listing gives the trade name, the other adds the code. If you see both on a comparison site, you are looking at one product twice.

A missing code is a warning sign. A seller who cannot name the tissue is either repackaging without knowing the source, or does not want you checking. This is the fastest test you can run on any listing.

What is actually inside the capsule

Peptides are short chains of amino acids. Amino acids are the building blocks of protein. When a chain is only two to four links long it behaves differently from a full protein, because it is small enough to move through the body in ways a large molecule cannot.

Peptide Complex A-4 is a component of Sigumir. It is a mix of those short chains, holding cartilage peptides and bone peptides together. The source material is natural cartilage and bone, not a single isolated sequence.

The daily serving is a stated number, not a proprietary complex. That matters more than it sounds, and it is covered further down.

Peptide deficiency and protein synthesis

You will see the phrase peptide deficiency all over this category. It is worth defining properly.

The idea from this research program is that tissues hold fewer of their own short peptides as the body ages. Supplying matching peptides may support normal protein synthesis at a cellular level. It may also support the metabolic processes a tissue already runs.

That is the hypothesis. It is not an established clinical finding, and I would rather define it plainly than let it sit in the background sounding more settled than it is.

Part two of twoCytomax and Cytogen: the split that matters

The second half of the label is the class. There are two, and this is where most of the real confusion sits.

Cytomax means natural. The peptides were extracted from actual tissue. Because tissue holds many short chains, a Cytomax gives you a mix rather than one molecule. Published descriptions put these preparations under 50 amino acids and under 5 kDa in mass. Larger material is filtered out.

Cytogen means synthetic. Researchers analysed a natural mix, identified the most active single peptide in it, and rebuilt that one sequence in a lab. A Cytogen gives you one molecule at a known amount.

	Cytomax	Cytogen
Origin	Extracted from tissues	Built in a lab
Contents	A mix of short peptides	One peptide sequence
Onset	Gradual	Faster
Duration	Longer lasting	Shorter lived
Usual role	The main course	The opening phase
Cartilage entry	Sigumir	Cartalax

Neither class is the upgrade. This trips people up constantly. Synthetic sounds more advanced and natural sounds more wholesome, and neither instinct helps you here. The benefits people report are spread across both, not concentrated in one.

They are timing tools. The synthetic arrives faster and fades faster. The natural arrives slower and holds longer. That is the whole difference, and it is why the conventional combination runs Cytogen first and Cytomax after.

So where does the Sigumir peptide sit

Sigumir is the A-4 Cytomax. Natural, extracted from the cartilage and bone tissues of young animals, holding a mix of short peptides rather than a single sequence.

When people search for a cartilage bioregulator, the Sigumir peptide is what they almost always mean. Sigumir is the cartilage peptide bioregulator in the natural line, and A-4 is its address in the catalog.

That places it as a main course product rather than an opener. It is the one you run for the longer stretch.

Sigumir also appears in two other formats worth knowing about. There is an EternaPeptix A-4 version, and a multi peptide complex called MUV 4 built for the musculoskeletal system.

There is no herb blend in the capsules, no vitamin stack, no proprietary formula. One peptide complex. The supplement aisle trained everyone to expect a long ingredient list, and bioregulators go the other way on purpose. Narrow is the design, not a shortcut.

If the category is new to you, our primer on what a peptide bioregulator is covers the background in one page.

Sigumir or Cartalax: how to actually choose

This is the question I get most, and the system above already answers it.

They are not competitors. Sigumir is the Cytomax and Cartalax is the Cytogen, both pointing at cartilage and bone tissues. Asking which is better is like asking whether primer or topcoat is better.

Three patterns cover almost everyone:

• Cartalax first, then Sigumir. The conventional sequence. Open with the synthetic, follow with the natural for the longer course.
• Sigumir on its own. Very common and completely reasonable. Most people who have been at this for years run the Cytomax and never touch the synthetic.
• Cartalax on its own. The least common of the three. It suits people who want a short defined block rather than an ongoing course.

If you want one recommendation instead of three options: start with the Sigumir A-4 capsules. It is the main course product, it has the direct tissue source, and if you only ever buy one thing in this group it should be that one.

The cartilage and bone group

Sigumir does not sit alone. Four peptide bioregulators relate to this tissue area, and knowing the map stops you buying the same thing twice.

Product	Code	Tissue	Class
Sigumir	A-4	Cartilage and bone	Cytomax
Cartalax	See note	Cartilage and bone	Cytogen
Bonomarlot	A-20	Bone marrow	Cytomax
Bonothyrk	A-21	Parathyroid	Cytomax

Bonothyrk is the one people skip and probably should not. The parathyroid glands help maintain calcium and phosphate balance, and calcium sits upstream of bone density and of everything else in this group.

The pre built option is the musculoskeletal system bundle, which pairs Sigumir with Ventfort (A-3, vascular), Vladonix (A-6, thymus) and Bonothyrk (A-21). Vascular is in there because circulation feeds every tissue, joint tissue included.

To build your own combination instead, the full bioregulator range lists every code we carry, and the joint health and bone health collections narrow it to this group.

Who tends to look at this group

Sigumir is marketed towards health-conscious adults interested in anti-aging and wellness. Adults over 35 are the primary target audience for Sigumir. Interest in the musculoskeletal system group is not evenly spread, and the pattern is fairly predictable.

Elderly people look at it most, and among them especially women, because bone density changes with age and shifts again after menopause. That is ordinary biology rather than a diagnosis.

The second group is people who load their joints and spine hard. That covers heavy lifting and high physical activity at work. It also covers both ends of the range where people exercise, the very active and the very sedentary. Both ends put unusual demand on joint tissue.

Even teenagers turn up in this category now. That is mostly general interest in mobility rather than anything else.

Anyone thinking about long term joint health may find this group worth reading about. None of that means a supplement is the answer for any of them. Movement, load, sleep and protein intake still do the heavy lifting for long term mobility. A peptide bioregulator sits alongside those things. It does not replace them, and no honest seller would tell you otherwise.

What the clinical research actually supports

Here is where I would rather lose a sale than oversell. The research is real, it is published, and it is narrower than most sellers imply.

The proposed mechanism has two halves.

Getting into the cells. A 2022 paper from the Khavinson group examined 26 ultrashort peptides and mapped which membrane transporters could plausibly carry them.³ This supports the idea that chains this small can enter cells through transport systems the body already runs for amino acids. It is a feasibility argument, and a good one.

Doing something once inside. A 2021 systematic review gathered the published work on short peptides and gene regulation.⁴ Peptides in Sigumir purportedly interact with DNA to stimulate protein synthesis. The word purportedly is doing real work in that sentence. It is the proposal the program puts forward, not a demonstrated fact about this capsule.

The framework behind all of it came out of the Saint Petersburg Institute of Bioregulation and Gerontology. Khavinson set it out in 2002¹ and summarised it again in 2009 after 35 years of development.²

The study closest to Sigumir itself

Most mechanism papers quoted online are not about Sigumir. The nearest verified match is a 2008 animal study led by Povorozniuk with Khavinson as co-author. It examined a preparation based on cartilaginous tissue extract and how bone tissues in ageing rats responded to it.⁵

That is an animal study, and it tested a preparation rather than the retail capsule. I am telling you plainly because the alternative is quoting someone else's data and hoping you do not check.

The honest limitations

Nearly all of this work originates from one research program. Independent replication outside it remains limited.

Put plainly: the scientific evidence supporting Sigumir's effectiveness is limited. Sigumir may support joint and spinal health at the cellular level, and that is a proposal rather than a proven outcome. Anyone telling you the case is settled is selling harder than the evidence allows.

Material from the research program also describes the effect of a natural bioregulator carrying on after a course ends. Figures of 3 to 6 months get quoted. I pass that on as their description, not as a promise about your results.

What we are not claiming

I would rather be blunt about this than let you fill in the blanks yourself.

Sigumir is categorized as a dietary supplement and not an FDA-approved medication. It is not a drug, and peptide bioregulators are not drugs. It is not a treatment for anything, it is not a form of disease prevention, and it is not intended to diagnose, treat, cure or prevent any disease. It is not offered for arthritis or rheumatism, and it is not sold to reduce pain or discomfort.

You will find sellers who imply all of the above. Some of them lift those words from older listings without checking what the research supports. The research does not support them, and a product that needed those claims would not need the rest of this page.

Sigumir is also not an injectable. It is an oral capsule. Research about injectable peptides describes a separate category of compound and does not describe this product.

How to spot an authentic listing

This line has attracted a lot of copies. Four checks, in order of how quickly they work:

1. Is the tissue code stated? A real listing says A-4 and says cartilage. No code is the fastest disqualifier there is.
2. Is the peptide amount a number? You should see a stated milligram figure per serving. Proprietary blend language hides how little is in there.
3. Does the sourcing name a line? A real answer names a European manufacturing line. A shipping country is not a source.
4. Are the claims boring? Anyone promising to rebuild your joints has told you they are not reading the research.

We have run this line since 2015 and ship every order from Washington State. Our about page covers the sourcing in full.

Running a course

Dosing, exact duration, storage and contraindications all live on the product page. Those details belong with the label, not in an article that can go stale.

The shape of it is simple. It is an oral capsule taken with meals. The usual dose of Sigumir is 1 to 2 capsules daily.

Why you see both one month and three months

Courses typically last between 1 to 3 months, and the range confuses people. It should not. The two numbers describe two different things.

One month is a single peptide course. That is Sigumir on its own, and it is what the label on our packs specifies.

Three months is a complex course. That is three different bioregulators run as a set rather than one peptide taken for longer. The three months counts the whole set, not three months of Sigumir.

So if you are taking Sigumir alone, your course is one month. The three month figure only applies once you are running a complex. That distinction is worth holding onto, because plenty of sellers quote the longer number while selling you a single peptide.

Bioregulators are built around courses rather than continuous use. Most people run one, take a break of a few months, then repeat.

Monitor for signs of intolerance like itching or swelling, and stop if any appear.

It is commonly combined with other supplements in the same group. Talk with your healthcare provider first if you take prescription medication. That is the one risk worth taking seriously here.

Common questions

What is the Sigumir peptide?

The A-4 natural complex, extracted from the cartilage and bone tissues of young animals. It is a Cytomax, so it holds a mix of cartilage peptides and bone peptides rather than one lab built sequence.

What does A-4 mean?

It is a tissue code. A-4 is cartilage and bone. Sigumir and Sigumir A-4 are the same product.

What is the difference between Cytomax and Cytogen?

Cytomax is extracted from tissues and holds a mix of peptides, acting gradually across a longer course. Cytogen is built in a lab and holds one sequence, acting faster but fading sooner.

Is Sigumir the same as Cartalax?

No. Same tissue area, different classes. Sigumir is the Cytomax, Cartalax is the Cytogen. They are usually run in combination or in sequence.

What is peptide deficiency?

The proposal that tissues hold fewer of their own short peptides with age. Supplying matching peptides may then support normal protein synthesis at a cellular level. It is a hypothesis from this program, not a settled clinical finding.

Does cartilage cells research apply to Sigumir?

No. Those findings come from work on synthetic peptide drug candidates, not dietary supplements, and not this product.

How long is a course?

Courses typically last between 1 to 3 months. One month is a single peptide course, which is Sigumir on its own. Three months is a complex course built from three different bioregulators. The usual dose is 1 to 2 capsules daily, taken with meals. Follow the label for exact duration.

How strong is the evidence?

The scientific evidence supporting Sigumir's effectiveness is limited. Most published work comes from a single research program and independent replication remains thin.

Can it be taken with other supplements?

It is commonly run in combination with others in this group. Check with your healthcare provider first if you take prescription medication.

Which peptides are in the cartilage and bone group?

Sigumir (A-4), Cartalax, Bonomarlot (A-20) and Bonothyrk (A-21).

Research references

1. Khavinson VKh. Peptides and Ageing. Neuroendocrinology Letters. 2002. PMID: 12374906
2. Khavinson VKh, Malinin VV. Gerontological aspects of genome peptide regulation, 35 years of experience. 2009. PMID: 19827673
3. Khavinson V, et al. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. International Journal of Molecular Sciences. 2022;23(14):7733. DOI: 10.3390/ijms23147733
4. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. DOI: 10.3390/molecules26227053
5. Povorozniuk VV, Khavinson VKh, Makogonchuk AV, Ryzhak GA, Kreslov EA, Gopkalova IV. Effect of peptide regulators on the structural and functional status of bone tissue in ageing rats. 2008. PMID: 18306703
6. Linkova N, Khavinson V, Diatlova A, Myakisheva S, Ryzhak G. Peptide Regulation of Chondrogenic Stem Cell Differentiation. International Journal of Molecular Sciences. 2023;24(9):8415. DOI: 10.3390/ijms24098415

References are provided for education. Citing a study is not a claim that this product produces the results described in it. Several papers above study compounds that are not dietary supplements.